Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07583810 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

StatusRecruiting
PhasePhase 2
Started2026-12-16
View on ClinicalTrials.gov ↗

Amendment history

2026-09-30
Recruitment opened
2026-05-12
Study Status, Conditions v1
Re-verified, no change to tracked fields
2026-05-07
Original filing
This phase II trial tests the effect of nemtabrutinib in combination with rituximab in treating patients with marginal zone lymphoma. Nemtabrutinib, a non-covalent Bruton's tyrosine kinase (BTK) inhibitor, may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nemtabrutinib in combination with rituximab may be safe, tolerable and/or effective in treating patients with marginal zone lymphoma.
Trial Details
NCT Number NCT07583810
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma, Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Lymphoma, Extranodal Marginal Zone Lymphoma
Enrollment 35 participants
Start Date 2026-12-16
Primary Completion 2028-05-02 (estimated)
Study Completion 2028-05-02 (estimated)
Updated on ClinicalTrials.gov 2026-09-29